FORM PTO-222
(REV. 4-85)

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INTERFERENCE DIGEST

JUL 17 1986

Interference No. 101,613 Paper No. 15

Name, Milton L. Hoefle et al

Serial No. 236,397 Patent No. 4,344,949

Title, SUBSTITUTED ACYL DERIVATIVES 1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACIDS

Filed, 02/20/81 issued 08/17/82

Interference with Suh et al

DECISION ON MOTIONS

Examiner-in-Chief, _____ Dated, _____

FINAL DECISIONS
~~DECISIONS ON PRIORITY~~

Board of Patent Appeals and Interferences, Favorable Dated, 4/30/91

Court, _____ Dated, _____

REMARKS

This should be placed in each application or patent involved in interference in addition to the interference letters.

The cases involved in this interference are:

Junior Party

Applicants: John T. Suh, Jeffrey N. Barton and John R. Regan

Addresses: 59 Stananwich Road, Greenwich, CT 06830
137 Florence Street, Yonkers, N.Y. 10704
4 Staub Court, Mamaroneck, N.Y. 10543

Serial No.: 245,407 filed 03/19/81

For: AMIDO-AMINO ACIDS

Assignee: None

Attorneys of Record: Ernest B. Lipscomb, III, Leon E. Tenenbaum and Gilbert W. Rudman

Associate Attorney: John F. Scully, Anthony C. Scott, Stephen D. Murphy, Leopold Presser, Peter G. Dilworth and William C. Roch

Accorded benefit of: None

Address: Peter G. Dilworth, Esq.
Scully, Scott, Murphy and Presser
200 Garden City Plaza
Garden City, N.Y. 11530

Senior Party

Patentees: Milton L. Hoefle and Sylvester Klutchko

Addresses: 2108 Brockman Boulevard, Ann Arbor, Mich. 48104
5143 Pratt Road, Ann Arbor, Mich. 48103

Serial No.: 236,397 filed 02/20/81 Now Patent No. 4,344,949 issued 08/17/82

For: SUBSTITUTED ACYL DERIVATIVES OF 1,2,3,4-TETRA-HYDROISOQUINOLINE-3-CARBOXYLIC ACIDS

Assignee: Warner-Lambert Company, Morris Plains, N.J.

Attorneys of Record: Albert H. Graddis, Stephen Raines, Stephen I. Miller, Walter Patton and Louis S. Gillow

Associate Attorney: None

Accorded benefit of: None

Address: Albert H. Graddis
201 Tabor Rd.
Morris Plains, N.J. 07950

Count 1

A substituted acyl compound of 1,2,3,4-tetrahydroisoquinoline having the formula



where
R and R_2 are hydrogen, C_1-C_6 alkyl, or phenyl C_1-C_6 alkyl;
R_1, R_4, R_5, R_6 and R_7 are independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_6-C_{10} aryl, fused C_6-C_{10} aryl-cyclo C_3-C_7 alkyl, C_6-C_{10} aryl C_1-C_6 alkyl, cyclo C_3-C_7 alkyl, or heterocyclic selected from the group consisting of pyridinyl, piperidinyl, morpholinyl, pyrrolyl, pyrrolidinyl, thiamorpholinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolindinyl, thiazolinyl, thiazolyl, imidazolidinyl, imidazolinyl, imidazolyl, thiophenyl, tetrahydrothiophenyl, furyl and tetrahydrofuryl, wherein the alkyl, alkenyl, and alkynyl groups may carry substituents selected from the group consisting of hydroxy, C_1-C_6 alkoxy, halo, amino, C_1-C_6 alkylamino, thio and C_1-C_6 alkylmercapto, the cycloalkyl groups may carry substituents selected from the group consisting of C_1-C_6 alkyl, halo, halo C_1-C_6 alkyl, hydroxy, C_1-C_6 alkylamino, nitro and trifluoromethyl, and the aryl and heterocyclic groups may carry substituents selected from the group consisting of C_1-C_6 alkyl, hydroxy, C_1-C_6 alkoxy, hydroxy C_1-C_6 alkyl, halo, thio, C_1-C_6 alkylmercapto, thio C_1-C_6 alkyl, halo C_1-C_6 alkyl, amino, C_1-C_6 alkylamino, amino C_1-C_6 alkyl, nitro, methylenedioxy, and trifluoromethyl;
R_3 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, nitro, amino, C_1-C_6 alkylamino, di C_1-C_6 alkylamino, hydroxy, C_1-C_6 alkoxy, thio, C_1-C_6 alkoxy, thio, lower alkylthio, lower alkylsulfinyl, C_1-C_6 alkylmercapto, lower alkylsulfonyl, hydroxy C_1-C_6 alkyl, thio C_1-C_6 alkyl, halogen, halo C_1-C_6 alkyl, amino C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, di C_1-C_6 alkylamino C_1-C_6 alkyl, sulfonamido, methylenedioxy, or trifluoromethyl and, where there is more than one R_3 group, the groups may be same or different;
n is an integer from 1 to 4 inclusive; and the pharmaceutically acceptable salts thereof.

The claims of the parties which correspond to this count are:

Suh et al:	Claims 2-26
Hoefle et al:	Claims 1-15

dal

Michael Sofocleous
Examiner-in-Chief
(703) 557-4015